REFERENCES
- Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739–761.
- Atkin K, Ahmad WI. Family care-giving and chronic illness: how patients cope with a child with sickle cell disorder or thalassaemia. Health Soc Care Community. 2000;8(1):57–69.
- Nick H, Acklin P, Lattmann R, Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003;10(12):1065–1076.
- Cappellini MD, Bejaoui M, Agaoglu L, Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther. 2007;29(5):909–917.
- Vullo C, Di Palma A. Compliance with therapy in Cooley's anaemia. Prog Clin Biol Res. 1989;309:43–49.
- Brittenham GM, Griffith PM, Nienhuis AW, Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567–573.
- Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26–36.
- Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes. 2006;4:73.
- Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051–2052.
- Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol. 2002;15(2):329–368.
- Borgna-Pignatti C, Rugolotto S, De Stefano P, Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193.
- Matsui D, Hermann C, Klein J, Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol. 1994;34(9):944–949.
- Delea TE, Edelsberg J, Sofrygin O, Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919–1929.
- Amico KR, Toro-Alfonso J, Fisher JD. An empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence. AIDS Care. 2005;17(6):661–673.
- Patterson JM, Budd J, Goetzz D, Warwick WJ. Family correlates of a 10-year pulmonary health trend in cystic fibrosis. Pediatrics. 1993;91(2):383–389.
- Siegfried N, Muller M, Volmink J, Male circumcision for prevention of heterosexual acquisition of HIV in men (Review). Cochrane Database Sysst Rev. 2008;4.
- Ward A, Caro JJ, Green TC. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol. 2002;2:3.
- Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol. 2001;56(12):915–922.
- Rosenstock LM. The health belief model and preventative health behaviour. Health Education Monographs. 1974;2(4):354–386.
- Ajzen I, Fishbein M. Understanding Attitudes and Social Behavior. Engelwood Cliffs: Prentice Hall. 1980.
- Johnson MJ. The medication adherence model: a guide for assessing medication taking. Res Theory Nurs Pract. 2002;16(3):179–192.
- Di Palma A, Barrai I, Candini G, Vullo C. Compliance alia terapia chelante dei soggeti affeti di Cooley. Riv Ital Ped. 1982;8183–187.
- Beratis S. Noncomliance with iron chelation therapy in patients with β thalassaemia. J Psychosom Res. 1989;33(6):739–745.
- Koch DA, Giardina PJ, Ryan M, MacQueen M, Hilgartner MW. Behavioral contracting to improve adherence in patients with thalassemia. J Pediatr Nurs. 1993;8(2):106–111.
- Goldbeck L, Baving A, Kohne E. Psychosocial aspects of β-thalassemia: distress, coping and adherence. (German) Klin Padiatr. 2000;212(5):354–259.
- Treadwell MJ, Weissman L. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Semin Hematol. 2001;38(1, Suppl. 1):77–84.
- Aydinok Y, Erermis S, Bukusoglu N, Yilmaz D, Solak U. Psychosocial implications of thalassemia major. Pediatr Int. 2005;47(1):84–89.
- Treadwell MJ, Law AW, Sung J, Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatr Blood Cancer. 2005;44(5):500–507.